Trial Profile
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Epacadostat (Primary) ; Retifanlimab (Primary) ; Dexamethasone
- Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma
- Focus Therapeutic Use
- 13 Jul 2023 Planned End Date changed from 30 Apr 2028 to 30 Apr 2026.
- 13 Jul 2023 Planned primary completion date changed from 31 Jan 2025 to 13 Apr 2024.
- 13 Jul 2023 Status changed from recruiting to active, no longer recruiting.